HK Stock Market Move | SINOMAB BIO-B(03681) rose more than 7% in the afternoon. The first cohort of healthy subjects in China completed dosing for the subcutaneous injection bridging study of SM17.

Sinomab Bio-B (03681) rose more than 7% in the afternoon, up 6.33% as of press time, at 1.68 Hong Kong dollars with a turnover of 11.7838 million Hong Kong dollars. On the news front, China Antibody announced that the bridging experiment of the SM17 subcutaneous injection formulation conducted in China on October 14th has successfully completed the first queue of dosing in healthy subjects. As of the date of this announcement, all subjects tolerated the medication well, and no adverse events were reported. This bridging experiment aims to study the safety, tolerability, pharmacokinetic characteristics of the SM17 subcutaneous injection formulation, and explore the human bioavailability of the SM17 subcutaneous injection formulation. A total of 30 healthy subjects are planned to be enrolled in this bridging trial. All healthy subjects are expected to be recruited by November 2025 and complete all follow-ups by March 2026. SM17 is a novel, globally pioneering humanized IgG4- monoclonal antibody that regulates the type II allergic reaction pathway by targeting the key molecule interleukin 25 (IL-25) receptor in the alertin pathway. The company believes that targeting upstream therapy of Th2 inflammatory cytokine pathways will have a broad effect on skin inflammation, meaning that SM17 has significant potential for safer and more effective and differentiated advantages in the treatment of atopic dermatitis.